Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients

Ashleigh C McEvoy, Lydia Warburton, Zeyad Al-Ogaili, Liesl Celliers, Leslie Calapre, Michelle R Pereira, Muhammad A Khattak, Tarek M Meniawy, Michael Millward, Melanie Ziman, Elin S Gray

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND: Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is a need to understand the correlation between ctDNA levels and the patients' overall metabolic tumour burden (MTB).

METHODS: Thirty-two treatment naïve metastatic melanoma patients were included in the study. MTB and metabolic tumour volume (MTV) was measured by 18F-fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT). Plasma ctDNA was quantified using droplet digital PCR (ddPCR).

RESULTS: CtDNA was detected in 23 of 32 patients. Overall, a significant correlation was observed between ctDNA levels and MTB (p < 0.001). CtDNA was not detectable in patients with an MTB of ≤10, defining this value as the lower limit of tumour burden that can be detected through ctDNA analysis by ddPCR.

CONCLUSIONS: We showed that ctDNA levels measured by ddPCR correlate with MTB in treatment naïve metastatic melanoma patients and observed a limit in tumour size for which ctDNA cannot be detected in blood. Nevertheless, our findings support the use of ctDNA as a non-invasive complementary modality to functional imaging for monitoring tumour burden.

Original languageEnglish
Article number726
JournalBMC Cancer
Volume18
Issue number1
DOIs
Publication statusPublished - 9 Jul 2018

Fingerprint

Tumor Burden
Melanoma
DNA
Neoplasms
Polymerase Chain Reaction
Glucose

Cite this

McEvoy, A. C., Warburton, L., Al-Ogaili, Z., Celliers, L., Calapre, L., Pereira, M. R., ... Gray, E. S. (2018). Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer, 18(1), [726]. https://doi.org/10.1186/s12885-018-4637-6
McEvoy, Ashleigh C ; Warburton, Lydia ; Al-Ogaili, Zeyad ; Celliers, Liesl ; Calapre, Leslie ; Pereira, Michelle R ; Khattak, Muhammad A ; Meniawy, Tarek M ; Millward, Michael ; Ziman, Melanie ; Gray, Elin S. / Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. In: BMC Cancer. 2018 ; Vol. 18, No. 1.
@article{5401f65acf4844e2a73b85dc3c074bb1,
title = "Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients",
abstract = "BACKGROUND: Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is a need to understand the correlation between ctDNA levels and the patients' overall metabolic tumour burden (MTB).METHODS: Thirty-two treatment na{\"i}ve metastatic melanoma patients were included in the study. MTB and metabolic tumour volume (MTV) was measured by 18F-fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT). Plasma ctDNA was quantified using droplet digital PCR (ddPCR).RESULTS: CtDNA was detected in 23 of 32 patients. Overall, a significant correlation was observed between ctDNA levels and MTB (p < 0.001). CtDNA was not detectable in patients with an MTB of ≤10, defining this value as the lower limit of tumour burden that can be detected through ctDNA analysis by ddPCR.CONCLUSIONS: We showed that ctDNA levels measured by ddPCR correlate with MTB in treatment na{\"i}ve metastatic melanoma patients and observed a limit in tumour size for which ctDNA cannot be detected in blood. Nevertheless, our findings support the use of ctDNA as a non-invasive complementary modality to functional imaging for monitoring tumour burden.",
author = "McEvoy, {Ashleigh C} and Lydia Warburton and Zeyad Al-Ogaili and Liesl Celliers and Leslie Calapre and Pereira, {Michelle R} and Khattak, {Muhammad A} and Meniawy, {Tarek M} and Michael Millward and Melanie Ziman and Gray, {Elin S}",
year = "2018",
month = "7",
day = "9",
doi = "10.1186/s12885-018-4637-6",
language = "English",
volume = "18",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

McEvoy, AC, Warburton, L, Al-Ogaili, Z, Celliers, L, Calapre, L, Pereira, MR, Khattak, MA, Meniawy, TM, Millward, M, Ziman, M & Gray, ES 2018, 'Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients' BMC Cancer, vol. 18, no. 1, 726. https://doi.org/10.1186/s12885-018-4637-6

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. / McEvoy, Ashleigh C; Warburton, Lydia; Al-Ogaili, Zeyad; Celliers, Liesl; Calapre, Leslie; Pereira, Michelle R; Khattak, Muhammad A; Meniawy, Tarek M; Millward, Michael; Ziman, Melanie; Gray, Elin S.

In: BMC Cancer, Vol. 18, No. 1, 726, 09.07.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients

AU - McEvoy, Ashleigh C

AU - Warburton, Lydia

AU - Al-Ogaili, Zeyad

AU - Celliers, Liesl

AU - Calapre, Leslie

AU - Pereira, Michelle R

AU - Khattak, Muhammad A

AU - Meniawy, Tarek M

AU - Millward, Michael

AU - Ziman, Melanie

AU - Gray, Elin S

PY - 2018/7/9

Y1 - 2018/7/9

N2 - BACKGROUND: Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is a need to understand the correlation between ctDNA levels and the patients' overall metabolic tumour burden (MTB).METHODS: Thirty-two treatment naïve metastatic melanoma patients were included in the study. MTB and metabolic tumour volume (MTV) was measured by 18F-fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT). Plasma ctDNA was quantified using droplet digital PCR (ddPCR).RESULTS: CtDNA was detected in 23 of 32 patients. Overall, a significant correlation was observed between ctDNA levels and MTB (p < 0.001). CtDNA was not detectable in patients with an MTB of ≤10, defining this value as the lower limit of tumour burden that can be detected through ctDNA analysis by ddPCR.CONCLUSIONS: We showed that ctDNA levels measured by ddPCR correlate with MTB in treatment naïve metastatic melanoma patients and observed a limit in tumour size for which ctDNA cannot be detected in blood. Nevertheless, our findings support the use of ctDNA as a non-invasive complementary modality to functional imaging for monitoring tumour burden.

AB - BACKGROUND: Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is a need to understand the correlation between ctDNA levels and the patients' overall metabolic tumour burden (MTB).METHODS: Thirty-two treatment naïve metastatic melanoma patients were included in the study. MTB and metabolic tumour volume (MTV) was measured by 18F-fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT). Plasma ctDNA was quantified using droplet digital PCR (ddPCR).RESULTS: CtDNA was detected in 23 of 32 patients. Overall, a significant correlation was observed between ctDNA levels and MTB (p < 0.001). CtDNA was not detectable in patients with an MTB of ≤10, defining this value as the lower limit of tumour burden that can be detected through ctDNA analysis by ddPCR.CONCLUSIONS: We showed that ctDNA levels measured by ddPCR correlate with MTB in treatment naïve metastatic melanoma patients and observed a limit in tumour size for which ctDNA cannot be detected in blood. Nevertheless, our findings support the use of ctDNA as a non-invasive complementary modality to functional imaging for monitoring tumour burden.

U2 - 10.1186/s12885-018-4637-6

DO - 10.1186/s12885-018-4637-6

M3 - Article

VL - 18

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 726

ER -

McEvoy AC, Warburton L, Al-Ogaili Z, Celliers L, Calapre L, Pereira MR et al. Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer. 2018 Jul 9;18(1). 726. https://doi.org/10.1186/s12885-018-4637-6